Clinical Trial Update: A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)

View source ↗

Summary

An update on a clinical trial evaluating adverse events and changes in disease state for oral upadacitinib in adolescents aged 12 to <18 with atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Status: COMPLETED